Table 3 Univariate analysis for EFS and OS among MLL-r positive ALL patients

 Male

Ref.

Ref.

 Female

5.0 (1.5, 17.5)

0.011

3.8 (1.2, 12.5)

0.025

  < 1

Ref.

Ref.

  ≥ 1, < 10

0.3 (0.1, 1.1)

0.072

0.3 (0.1, 1.3)

0.101

  ≥ 10

0.1 (0.0, 0.8)

0.028

0.2 (0.0, 2.2)

0.183

 GD-ALL-2008 Protocol

Ref.

Ref.

 SCCLG-ALL-2016 Protocol

1.2 (0.4, 3.1)

0.745

1.4 (0.1, 17.6)

0.771

  < 50 × 10⁹/L

Ref.

Ref.

  ≥ 50 × 10⁹/L

2.7 (1.1, 7.1)

0.039

16.9 (1.5, 185.3)

0.021

  < 110 g/L

Ref.

Ref.

  ≥ 110 g/L

0.8 (0.2, 3.8)

0.797

1.5 (0.6, 4.0)

0.425

  < 100 × 10⁹/L

Ref.

Ref.

  ≥ 100 × 10⁹/L

0.2 (0.0, 1.9)

0.175

0.6 (0.2, 1.5)

0.260

 SR

Ref.

Ref.

 IR

1.6 (0.3, 7.5)

0.576

4.9 (0.5, 47.5)

0.170

 HR

1.8 (0.5, 6.8)

0.399

1.7 (0.1, 26.8)

0.717

 B -cell

Ref.

Ref.

 T-cell

6.7 (1.5, 29.6)

0.012

2.8 (1.1, 7.1)

0.031

 MLL-PTD

Ref.

Ref.

 MLL-AF4

4.8 (1.4, 17.1)

0.015

6.4 (1.6, 24.8)

0.007

 MLL-ENL

1.2 (0.2, 7.0)

0.872

1.7 (0.1, 26.8)

0.717

 Others

0.9 (0.1, 5.3)

0.882

1.2 (0.1, 19.9)

0.883

 PGR

Ref.

Ref.

 P PR

1.8 (0.5, 6.7)

0.399

2.0 (0.6, 7.4)

0.285

 M1

Ref.

Ref.

 M2/M3

1.4 (0.4, 4.7)

0.633

2.0 (0.6, 6.6)

0.243

 M1

Ref.

Ref.

 M2/M3

1.0 (0.2, 4.2)

0.960

0.5 (0.0, 9.9)

0.683

  < 0.1%

Ref.

Ref.

  ≥ 0.1%

3.6 (1.1, 12.4)

0.041

5.8 (1.2, 29.0)

0.031

  < 0.01%

Ref.

Ref.

  ≥ 0.01%

0.5 (0.1, 3.8)

0.498

2.1 (0.4, 10.1)

0.360

 No

Ref.

Ref.

 Yes

0.4(0.2, 0.9)

0.027

0.1 (0.0, 0.8)

0.027